NASDAQ:INDP Indaptus Therapeutics Q3 2026 Earnings Date & Estimates $3.24 -0.26 (-7.43%) Closing price 04:00 PM EasternExtended Trading$3.23 -0.01 (-0.31%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Indaptus Therapeutics is estimated to report Q3 2026 earnings on Tuesday, November 17, 2026, before market opens. The conference call is scheduled for November 13, 2026 at 9:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 17, 2026TimeBefore Market OpensConference Call DateNovember 13, 2026Conference Call9:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Indaptus Therapeutics in Q3 2026Indaptus Therapeutics is expected to post earnings of -$1.46 per share. In the same quarter a year earlier Indaptus Therapeutics reported -$2.98 per share. Indaptus Therapeutics last reported on August 13, 2026, posting -$0.02 per share and beating the -$1.57 consensus estimate. Indaptus Therapeutics has beaten the consensus EPS estimate in 7 of its last 8 quarters.Consensus EstimatesConsensus EPS-$1.46Prior-Year EPS-$2.98Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.02 (Beat by +$1.55)EPS Beat Rate7 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Indaptus Therapeutics Q3 2026 Earnings FAQ When does Indaptus Therapeutics report Q3 2026 earnings? Indaptus Therapeutics (NASDAQ:INDP) is estimated to report Q3 2026 earnings on Tuesday, November 17, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Indaptus Therapeutics' Q3 2026 earnings call? Indaptus Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Indaptus Therapeutics? Analysts expect Indaptus Therapeutics to post earnings of -$1.46 per share for Q3 2026. Indaptus Therapeutics Earnings HeadlinesIndaptus Therapeutics Extends Timeline for Private Placement FinancingSeptember 30, 2026 | tipranks.comIndaptus Therapeutics Shares Rise After Entering $24 Million Private PlacementSeptember 10, 2026 | finance.yahoo.comU.S. Army Advances 75-Year Rare Earth Deal With Nasdaq FirmThe Pentagon is moving to cut US dependence on Chinese rare earth metals, and a Nasdaq-listed company just signed a term sheet for a potential 75-year agreement with the US Army. The proposed deal would let the company build and operate a rare earth processing facility on an active military base, with the Army getting first right to production. New Pentagon restrictions on Chinese-origin rare earth magnets take effect January 1, 2027. The company's mine-to-magnet platform covers feedstock agreements, processing, metallization, and downstream manufacturing, with commercial output targeted for 2027.November 3 at 1:00 AM | The Tomorrow Investor (Ad)Indaptus Therapeutics Announces Routine Board Member ResignationSeptember 4, 2026 | tipranks.comIndaptus Updates ATM Agreement to Expand Capital FlexibilitySeptember 1, 2026 | tipranks.comIndaptus Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update August 13, 2026 | quiverquant.comQSee More Indaptus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Indaptus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Indaptus Therapeutics and other key companies, straight to your email. Email Address About Indaptus TherapeuticsIndaptus Therapeutics (NASDAQ:INDP) is a clinical-stage biotechnology company developing immunotherapies designed to stimulate the body’s immune system to fight cancer and other serious diseases. The company’s approach is based on using attenuated or inactivated bacterial agents to activate multiple components of the immune response. Indaptus’ lead product candidate is Decoy20, an investigational, systemically administered bacterial immunotherapy. The treatment is designed to engage innate and adaptive immune pathways and potentially improve the body’s ability to recognize and attack tumor cells. The company has been evaluating Decoy20 in clinical studies involving patients with advanced solid tumors. Indaptus is focused primarily on advancing its proprietary bacterial immunotherapy platform through clinical development and exploring potential applications in oncology and other disease areas. As an emerging biotechnology company, its programs remain investigational and are subject to clinical, regulatory and commercial development risks.View Indaptus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Marriott's Earnings Beat Shows Why It's More Than a Bet on Travel DemandPalantir's $2.3 Billion Quarter Puts Its Premium Valuation to the TestApple's Earnings Beat Comes With a Catch for Investors Heading Into the HolidaysRepublic Services Has the Momentum, But Waste Management Has Another AdvantageAre the Fears Around Alphabet’s Search Slowdown Warranted?Alphabet's Golden Dome Talks Could Open a New Market, But How Much Is at Stake?Streaming Success: Fox Corp Channels Tubi For Q1 Earnings Beat Upcoming Earnings McDonald's (11/4/2026)DoorDash (11/4/2026)MercadoLibre (11/4/2026)Cenovus Energy (11/4/2026)Aflac (11/4/2026)Allstate (11/4/2026)MetLife (11/4/2026)Manulife Financial (11/4/2026)Cencora (11/4/2026)CVS Health (11/4/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
